Le Lézard
Classified in: Health
Subject: TRI

NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms



RARITAN, N.J., Oct. 5, 2017 /PRNewswire/ -- Janssen Research & Development, LLC and its development partner Bayer today announced the Phase III NAVIGATE ESUS study, evaluating the efficacy and safety of XARELTO® (rivaroxaban) for the secondary prevention of stroke and systemic embolism in patients with a recent embolic stroke of undetermined source (ESUS), is stopping early for futility. This decision is based on the recommendation of the study's Independent Data Monitoring Committee (IDMC) as the trial showed comparable efficacy between rivaroxaban and the standard of care, aspirin, and little chance of rivaroxaban showing an overall benefit versus aspirin if the study were to be completed. While bleeding rates were very low overall and within the expected range, an increase in bleeding was observed in the rivaroxaban arm compared to aspirin.

Janssen Pharmaceuticals Logo (PRNewsFoto/Janssen Pharmaceuticals, Inc.)

ESUS refers to patients with embolic stroke of unknown origin in whom common causes such as atrial fibrillation and carotid artery stenosis have been excluded.  It is estimated to affect approximately 500,000 people in the United States annually.

"XARELTO® is a highly effective anticoagulant for patients at risk for stroke from atrial fibrillation, as well as for the prevention and treatment of clots in a variety of approved indications," said Paul Burton, MD, PhD, FACC, Vice President, Medical Affairs, Janssen. "Results from ROCKET AF and emerging real-world data continue to show the positive benefit of XARELTO® in preventing cardiovascular events, including stroke."

The Phase III NAVIGATE ESUS trial enrolled approximately 7,200 patients from 459 sites across 31 countries worldwide. In the study, patients were randomized to receive either rivaroxaban 15 mg once daily or aspirin 100 mg once daily alone. The primary efficacy endpoint was a composite of stroke and systemic embolism; the primary safety endpoint was major bleeding. A complete data analysis is expected to be presented in 2018.

WHAT IS XARELTO®?
XARELTO® is a prescription medicine used to reduce the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem. For patients currently well managed on warfarin, there is limited information on how XARELTO® and warfarin compare in reducing the risk of stroke.

XARELTO® is also a prescription medicine used to treat deep vein thrombosis and pulmonary embolism, and to help reduce the risk of these conditions occurring again.

XARELTO® is also a prescription medicine used to reduce the risk of forming a blood clot in the legs and lungs of people who have just had knee or hip replacement surgery.

IMPORTANT SAFETY INFORMATION

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO®?

You may have a higher risk of bleeding if you take XARELTO® and take other medicines that increase your risk of bleeding, including:

Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above.

Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding:

Spinal or epidural blood clots (hematoma): People who take a blood thinner medicine (anticoagulant) like XARELTO®, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if:

If you take XARELTO® and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness, (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence).

XARELTO® is not for patients with artificial heart valves.

WHO SHOULD NOT TAKE XARELTO®?
Do not take XARELTO® if you:

WHAT SHOULD I TELL MY DOCTOR BEFORE OR WHILE TAKING XARELTO®?
Before taking XARELTO®, tell your doctor if you:

Tell all of your doctors and dentists that you are taking XARELTO®. They should talk to the doctor who prescribed XARELTO® for you before you have any surgery, medical or dental procedure.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way XARELTO® works. Certain medicines may increase your risk of bleeding. See "What is the most important information I should know about XARELTO®?"

Especially tell your doctor if you take:

Ask your doctor if you are not sure if your medicine is one listed above. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

HOW SHOULD I TAKE XARELTO®?

Take XARELTO® exactly as prescribed by your doctor.

Do not change your dose or stop taking XARELTO® unless your doctor tells you to.

If you take XARELTO® for:

WHAT ARE THE POSSIBLE SIDE EFFECTS OF XARELTO®?

Please see "What is the most important information I should know about XARELTO®?"

Tell your doctor if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You are also encouraged to report side effects to the FDA: visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736).

Please click here for full Prescribing Information, including Boxed Warnings, and Medication Guide.

Trademarks are those of their respective owners.

Janssen and Bayer together are developing rivaroxaban.

For more information about XARELTO®, visit www.xarelto.com.

About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us on Twitter at @JanssenUS.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the benefits of XARELTO® (rivaroxaban). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under "Item 1A. Risk Factors," its most recently filed Quarterly Report on Form 10-Q, including under the caption "Cautionary Note Regarding Forward-Looking Statements," and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Media Contact:
Sarah Freeman
Tel: (215) 510-4758
sfreem21@its.jnj.com

Christina Chan
Tel: (908) 927-5769
Cell: (908) 635-2406
Cchan20@its.jnj.com

Investor Relations Contacts:
Johnson & Johnson
Joseph J. Wolk 
Tel: (732) 524-1142

Lesley Fishman
Tel: (732) 524-3922

SOURCE Janssen Research & Development, LLC


These press releases may also interest you

at 12:30
DUBLIN, October 18, 2017 /PRNewswire/ -- The "Global Circulating Tumor Cell (CTC) Diagnostics Market 2017-2021" report has been added to Research and Markets' offering. The global circulating tumor cell (CTC) diagnostics market to grow at a CAGR...

at 12:30
HOUSTON, Oct. 18, 2017 /PRNewswire-USNewswire/ -- The college football season is heating up and this year's American Heart Association (AHA) Paul "Bear" Bryant Awards Watch List includes a who's who lineup of new faces and old favorites. Representing...

at 12:29
STOCKHOLM, October 18, 2017 /PRNewswire/ -- Today at the United Nations headquarters in New York, Essity, a leading global hygiene and health company, convened the fifth annual UN Foundation Dialogue on the Global Agenda. The Dialogue brought...

at 12:24
SAN RAFAEL, Calif., Oct. 18, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases....

at 12:00
DUBLIN, October 18, 2017 /PRNewswire/ -- The "Global Point-of-Care Testing Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024" report has been added to Research and Markets' offering. Global point-of-care...

at 12:00
TIANJIN, China, Oct. 18, 2017 /PRNewswire/ -- Asymchem Laboratories (Tianjin) Co., Ltd. (SHE: 002821, "Asymchem") today announced that its API facility, Jilin Asymchem Laboratories Co., Ltd. in P.R. China, ("Dunhua"), has successfully passed an...




News published on 5 october 2017 at 16:15 and distributed by: